DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

This study tests a new drug called DZD6008 in combination with other cancer medications for patients with advanced non-small cell lung cancer (NSCLC) that has a specific mutation in the EGFR gene. The goal is to find a more effective first-line treatment combination for this type of lung cancer. **You may be eligible if...** - You are 18 or older - You have advanced or metastatic non-squamous NSCLC confirmed by a lab test - Your cancer has a specific EGFR mutation (a gene change that drives the cancer) - You have not previously received treatment for advanced disease **You may NOT be eligible if...** - You have received prior treatment for advanced lung cancer - You have certain other EGFR mutations that are not covered by this drug - You have serious heart, liver, or lung problems Talk to your doctor to see if this trial is right for you.